The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke
Open accessAbstract
BACKGROUND: Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate of recurrence. Therefore, we investigated whether warfarin, which is effective and superior to aspirin in the prevention of cardiogenic embolism, would also prove superior in the prevention of recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke. METHODS: In a multicenter, double-blind, randomized trial, we compared the effect of warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that of aspirin (325 mg per day) on the combined primary end point of recurrent ischemic stroke or death from any cause within two years. RESULTS: The two randomized study groups were similar with respect to base-line risk factors. In the intention-to-treat analysis, no significant differences were found between the treatment groups in any of the outcomes measured. The primary end point of death or recurrent ischemic stroke was reached by 196 of 1103 patients assigned to warfarin (17.8 percent) and 176 of 1103 assigned to aspirin (16.0 percent; P=0.25; hazard ratio comparing warfarin with aspirin, 1.13; 95 percent confidence interval, 0.92 to 1.38). The rates of major hemorrhage were low (2.22 per 100 patient-years in the warfarin group and 1.49 per 100 patient-years in the aspirin group). Also, there were no significant treatment-related differences in the frequency of or time to the primary end point or major hemorrhage according to the cause of the initial stroke (1237 patients had had previous small-vessel or lacunar infarcts, 576 had had cryptogenic infarcts, and 259 had had infarcts designated as due to severe stenosis or occlusion of a large artery). CONCLUSIONS: Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage. Consequently, we regard both warfarin and aspirin as reasonable therapeutic alternatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In such patients oral vitamin K antagonists are not superior to aspirin but are associated with a higher bleeding risk.512,513”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [512]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators* (1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,525
Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
Ezekowitz, M. D., Bridgers, S. L., James, K. E., Carliner, N. H., Colling, C. L., Gornick, C. C., Krause-Steinrauf, H. J., Kurtzke, J. F., Nazarian, S. M., Radford, M. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272002 · Cited by 1,204
Hass, W. K., Easton, J. D., Adams, H. P., Pryse-Phillips, W. E. M., Molony, B. A., Anderson, S., Kamm, B., & for the Ticlopidine Aspirin Stroke Study Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198908243210804 · Cited by 1,194
Self-citationWarfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
Barnes, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,072
Flagged first, then by citations
Research works printed but not linked: 4
- 1980, Lancet, 2, 989
- Thompson JLP, 1994, Ann Neurol, 36, 305
- 10.2307/2281868 · DOI · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Sorted by citations
Items 701–800 of 999
CHADS2 and CHA2DS2-VASc Scores Can Guide the Evaluation of Cryptogenic Ischemic Stroke
Ekizoğlu, E., Atmaca, M. M., Balcıoğlu, Ç. Ç., Yeşilot, N., & Çoban, O. (2021) · Neurology India · doi:10.4103/0028-3886.333477 · Cited by 4
Vascular Diseases of the Nervous System
Biller, J., Love, B. B., & Schneck, M. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00062-1 · Cited by 4
Frost, E. D., Kamen, S. E., Oak, S., Higham, C., Thau, L., Vigilante, N. F., Wolfe, J., Thon, J. M., Schumacher, H. C., & Siegler, J. E. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106750 · Cited by 4
Coutsoumbas, G. V., & Pasquale, G. D. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac079 · Cited by 4
Eppler, M., Singh, N., Ding, L., Magee, G. A., & Garg, P. K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071550 · Cited by 4
Feldmann, E. G. (2005) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/j.scds.2005.12.002 · Cited by 4
Strokes and congenital heart disease in infants and children
Caldwell, R. L. (2003) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/j.scds.2004.02.005 · Cited by 4
Endovascular Management of Extracranial Carotid and Vertebral Disease
Thorisson, H. M., & Johnson, M. H. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.07.011 · Cited by 4
“Despite medical therapy with warfarin or aspirin, these patients have a high recurrence and death rate, reported as 16% to 18%.(22)”
White, H., & Jamieson, D. G. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2238 · Cited by 4
“8.(6) In ESPRIT,(9) the goal INR was 2 to 3.”
BackgroundWahl, D. G., Perret‐Guillaume, C., & Pietté, J. C. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.05.013 · Cited by 4
Randomized clinical stroke trials in 2003
Rabadi, M. H., & Blass, J. P. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0055-0 · Cited by 4
Management of Thrombosis in Antiphospholipid Syndrome
Khamashta, M. A., & Ruiz‐Irastorza, G. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_43 · Cited by 4
Sténoses athéroscléreuses des artères carotides internes
Touzé, E., & Mas, J. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2006.11.003 · Cited by 4
Evaluation and management of acute ischemic stroke
Bendixen, B. H., & Ocava, L. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0028-2 · Cited by 4
“The Warfarin Aspirin Recurrent Stroke Study (WARSS) [ 40 ] compared warfarin, at a dose adjusted to maintain an INR of 1.4 to 2.8, versus aspirin 325 mg/d, in patients without high-risk cardioembolic source or indication for endarterectomy.”
BackgroundMethodInfluentialZorowitz, R. D., Smout, R. J., Gassaway, J. A., & Horn, S. D. (2005) · Topics in Stroke Rehabilitation · doi:10.1310/ewcy-lj68-lhe0-54af · Cited by 4
Kirshner, H. S. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5667-4 · Cited by 4
Antiplatelet Agents and Arterial Thrombosis
Billett, H. H. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.09.002 · Cited by 4
Antithrombotic agents in cerebral ischaemia.
Dalal, P. M., Mishra, N. K., Bhattacharjee, M., & Bhat, P. (2006) · PubMed · Cited by 4
Neurologic complications of cardiomyopathies and other myocardial disorders
Moran, J. F. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4086-3.00009-6 · Cited by 4
Analysis of Hemorrhage Volumes After Angiogram-Negative Subarachnoid Hemorrhage
Bray, D. P., Ellis, J. A., Lavine, S. D., Meyers, P. M., & Connolly, E. S. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.07.019 · Cited by 4
Cifu, A. S., & Prasad, V. K. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3761-8 · Cited by 4
“Lastly, we know from older data that warfarin provides no benefit over aspirin for stroke patients who are not diagnosed with atrial fibrillation while in the hospital.(8) Certainly a subset of these patients had undetected atrial fibrillation.”
BackgroundPenetrating and Branch Artery Disease
Caplan, L. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4721-6.50010-9 · Cited by 4
Ishikawa, E., Yasaka, M., & Okada, Y. (2013) · Nosotchu · doi:10.3995/jstroke.35.425 · Cited by 4
Antiplatelet Therapy for Secondary Prevention of Stroke
Weksler, B. B. (2004) · Elsevier eBooks · doi:10.1016/b0-44-306600-0/50065-1 · Cited by 4
Patent foramen ovale and cryptogenic stroke: a complex neuro–cardio–vascular problem
Spies, C., & Wong, M. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.114 · Cited by 4
Manifestaciones neurológicas en el síndrome antifosfolipídico
Álvarez, L. S., Hughes, G. R. V., & Khamashta, M. A. (2005) · Medicina Clínica · doi:10.1157/13074395 · Cited by 4
Kenner, M., & Kelley, R. E. (2005) · Comprehensive Therapy · doi:10.1007/s12019-005-0006-x · Cited by 4
Jonas, S., & Grieco, G. (2006) · Cerebrovascular Diseases · doi:10.1159/000092330 · Cited by 4
“In this issue of Cerebrovascular Diseases , Sacco et al. [1] report subgroup analyses for the previously reported Warfarin-Aspirin Recurrent Stroke Study (WARSS) [ 2 ] . They conclude that antiplatelet therapy rather than warfarin ‘should be the mainstay of secondary stroke prevention after noncardioembolic stroke’.”
Preventing ischemic stroke in the older adult.
Ling, G. S. F., & Ling, S. M. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.suppl_3.s14 · Cited by 4
Eimil, M., & Egido, J. A. (2003) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(03)75904-0 · Cited by 4
Antithrombotic trials in acute ischaemic stroke: a selective review
Burger, K., & Tuhrim, S. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.2.303 · Cited by 4
“Warfarin has no role in the management of acute cerebral infarct, nor has it shown to be any more effective than aspirin for recurrent noncardiogenic stroke prevention [13].”
BackgroundKikuno, M., & Ueno, Y. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22026 · Cited by 3
PFO Closure for Cryptogenic Stroke: Review of New Data and Results
Rao, S., & Sila, C. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0243-8 · Cited by 3
Patent Foramen Ovale and Atrial Septal Defect
Aoun, J., Hatab, T., Volpi, J. J., & Lin, C. H. (2024) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2026.01.009 · Cited by 4
Paiva, L., Dinis, P., Providencia, R. A., Costa, M. A. D. S., Margalho, S., & Gonçalves, L. M. M. (2015) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2014.08.009 · Cited by 3
“O tamanho médio dos dispositivos de encerramento foi de 24 (9-35) mm.”
BackgroundAntithrombotics in heart failure: Background to the WARCEF study
Pullicino, P. M., & THOMPSON, J. (2003) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/scds.2003.00019 · Cited by 3
Self-citationRisks of Stroke from General Surgical Procedures in Stroke Patients
Bernstein, R. A. (2006) · Neurologic Clinics · doi:10.1016/j.ncl.2006.06.002 · Cited by 3
Marks, M. P., Schwamm, L. H., Johnston, S. C., Katzan, I. L., Kelly‐Hayes, M., Goldstein, L. B., Gorelick, P. B., Halperin, J. L., Sacco, L., Adams, R. J., et al. (2010) · Cited by 3
Self-citationCui, A., Kim, Y. H., Ghim, J., Jung, J. A., Cho, S., Choe, S., Choi, H. Y., Bae, K., & Lim, H.-S. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1629042 · Cited by 3
“Cilostazol shows appreciable inter-individual variation in bioavailability, and the coefficient of variation in most of these pharmacokinetic (PK) parameters of cilostazol ranges from 40% to 60% (Mohr et al., 2001).”
BackgroundLohanathan, A., Jacob, J. M., & Aaron, S. (2020) · Current Medical Issues · doi:10.4103/cmi.cmi_2_20 · Cited by 3
Brutto, V. J. D., Rundek, T., & Sacco, R. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-69424-7.00017-x · Cited by 4
Self-citationAtrial fibrillation: focus on monitoring strategies after cryptogenic stroke
BUONO, M. G. D., & SANNA, T. (2022) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05851-8 · Cited by 3
Stornello, M., Cappellani, R., Micieli, G., Sacco, S., Spolveri, S., Sterzi, R., Toni, D., & Carolei, A. (2016) · Italian Journal of Medicine · doi:10.4081/itjm.2016.682 · Cited by 3
Implantable Cardiac Rhythm and Hemodynamic Monitors
Daly, M. G., Melton, I., & Crozier, I. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37804-8.00025-0 · Cited by 3
Moțățăianu, A., Maier, S., Gothard, A., Bajkó, Z., & Bălașa, R. (2018) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2018-0008 · Cited by 3
“[18] Compared to oral antivitamin K, anticoagulant treatment with LMWH has proved to be more efficient in preventing recurrent deep vein thrombosis in cancer patients.[19,20] In contrast, in patients with NBTE, it is not clear which systemic anticoagulant treatment is optimal for secondary embolism prevention.”
BackgroundOrale Antikoagulation bei symptomatischen intrakraniellen Stenosen
Block, F., & Hoang, P. A. (2003) · Der Nervenarzt · doi:10.1007/s00115-003-1521-6 · Cited by 3
What's New in Stroke? The Top 10 for 2004/05
Tonarelli, S. B., & Hart, R. G. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00666.x · Cited by 3
Acute Stroke Care: A Manual from the University of Texas - Houston Stroke Team
Uchino, K., Pary, J. K., & Grotta, J. C. (2009) · Cited by 3
Resistencia a la aspirina en paciente con ictus isquémico reciente
Castilla‐Guerra, L., Navas-Alcantara, M. S., & Fernández-Moreno, M. C. (2013) · Revista Clínica Española · doi:10.1016/j.rce.2013.10.003 · Cited by 3
Biller, J. (2008) · Neurological Research · doi:10.1179/016164108x323744 · Cited by 3
Anticoagulation in Ischemic Stroke: Opportunities in Arterial Disease
van Gijn, J., & Algra, A. (2005) · Cerebrovascular Diseases · doi:10.1159/000089362 · Cited by 3
“Anticoagulation with lower intensity is probably safer in this group of patients, but is it effective? This approach was studied in the American WARSS trial [”
ResultAspirin resistant patients with recent ischemic stroke
Castilla‐Guerra, L., Navas-Alcantara, M. S., & Fernández-Moreno, M. C. (2013) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2013.12.002 · Cited by 3
Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack
Katz, B. S., & Flemming, K. D. (2014) · Neurosurgical FOCUS · doi:10.3171/2013.10.focus13402 · Cited by 3
Expert opinion on emerging drugs in childhood arterial ischemic stroke
Ng, J., & Ganesan, V. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.565050 · Cited by 3
“There has been a single nonrandomized retrospective study comparing aspirin (4 mg/kg) to low dose low-molecular-weight heparin (LMWH) in 135 children with AIS [60].”
BackgroundVrints, C. J., Wood, D., Zamorano, J. L., Zannad, F. M., Karadeniz, Ş., Mezzani, A., Prescott, E., Ebrahim, S. B. J., Germanò, G., Hobbs, R. F., et al. (2013) · Cited by 3
Conduct of Stroke-Related Clinical Trials
Tilley, B. C., & Palesch, Y. Y. (2004) · Elsevier eBooks · doi:10.1016/b0-44-306600-0/50069-9 · Cited by 3
Large Artery Occlusive Disease of the Anterior Circulation
Caplan, L. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4721-6.50008-0 · Cited by 3
Taking care of volunteers in a stroke trial: a new assisted-management strategy
Stuart, A., Sico, J. J., Viscoli, C. M., Tayal, A. H., Inzucchi, S. E., Ford, G. A., Furie, K. L., Côté, R., Spence, J. D., Tanné, D., et al. (2016) · Stroke and Vascular Neurology · doi:10.1136/svn-2016-000029 · Cited by 3
Self-citationMojadidi, M. K., Zaman, M. O., & Patel, N. K. (2018) · Stroke · doi:10.1161/strokeaha.118.021403 · Cited by 3
Bendahmash, A., Almanie, S., & Alwadai, A. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2972 · Cited by 3
TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECTS AND PATENT FORAMEN OVALE USING THE AMPLATZER® DEVICES
Patel, H., Cao, Q. L., & Hijazi, Z. M. (2004) · Elsevier eBooks · doi:10.1016/b978-0-323-02238-5.50022-x · Cited by 3
Greer, D. M., Beekman, R. B., Johnson, M. H., & Huttner, A. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-03283-8_5 · Cited by 3
PFO Closure for Cryptogenic Stroke
Gillow, S. J., & Lee, V. H. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0525-6 · Cited by 3
Warfarin or Aspirin for Recurrent Ischemic Stroke
Butera, G., Chessa, M., & Carminati, M. (2002) · New England Journal of Medicine · doi:10.1056/nejm200204113461514 · Cited by 3
Marti, J., & Antón, E. (2005) · Stroke · doi:10.1161/01.str.0000157947.89347.d8 · Cited by 3
Antiphospholipid syndrome: treatment controversies
Ruiz‐Irastorza, G., & Khamashta, M. A. (2006) · Future Rheumatology · doi:10.2217/17460816.1.3.345 · Cited by 3
“This was a subgroup analysis of a previously published randomized clinical trial, the Warfarin versus Aspirin Recurrent Stroke Study (WARSS), which compared low-intensity anticoagulation with aspirin for the secondary prevention of stroke [27].”
MethodAntithrombotic medication for stroke prevention
Weimar, C., Weber, R., & Diener, H. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.73 · Cited by 3
Drug Therapy of Neurovascular Disease
Weinberger, J. M., Frishman, W. H., & Terashita, D. M. (2003) · Cardiology in Review · doi:10.1097/01.crd.0000053459.09918.92 · Cited by 3
“The Warfarin Aspirin Recurrent Stroke Study has recently shown no benefit of warfarin over aspirin in the prevention of recurrent non-cardioembolic ischemic stroke (227).”
BackgroundTreating lacunar strokes occurring on aspirin
Castilla‐Guerra, L., & Sacco, R. L. (2014) · Neurology · doi:10.1212/wnl.0000000000000092 · Cited by 3
Self-citationLong-term anticoagulation therapy in prevention of stroke
Sherman, D. G. (2002) · Current Treatment Options in Neurology · doi:10.1007/s11940-002-0008-2 · Cited by 3
White, C. J. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_84 · Cited by 3
Confronting the Christmas of our health care discontent
Lewis, S. J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041665 · Cited by 3
“Lacunarization” of Stroke Prevention Studies
Chaturvedi, S. (2004) · Stroke · doi:10.1161/01.str.0000140889.23517.d8 · Cited by 3
Cerebrovascular Disease/Transient Ischemic Attack
Shaltoni, H. M., & Yatsu, F. M. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_92 · Cited by 3
Eimer, M. J., & Rajamannan, N. M. (2003) · New England Journal of Medicine · doi:10.1056/nejm200304173481620 · Cited by 3
Warfarin versus Aspirin in Heart Failure and Sinus Rhythm
Shah, S., Parra, D., & Rosenstein, R. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1207385 · Cited by 3
Vemulapalli, S., & Patel, M. R. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009558 · Cited by 3
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch19 · Cited by 3
Jeong, D.-Y., Ahn, J. H., Choi, W., Lee, H.-B., Kweon, J. Y., Oh, H., Kwon, S. U., Lee, J. S., Sung, M., Oh, D., et al. (2026) · Stroke · doi:10.1161/strokeaha.125.053896 · Cited by 2
Bradshaw, K. P., Holsten, J., Hahn, O., Foltz, A. G., Zera, K. A., Zhu, L., Haarslev, C., Wyss‐Coray, T., Peterson, T. C., & Buckwalter, M. S. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03774-7 · Cited by 2
“Finally, targeting the enhanced coagulation processes that we see in brain neutrophils reduces stroke sizes [111–113].”
Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., & Creager, M. A. (2014) · Cited by 2
Rivaroxaban in secondary prevention of cardioembolic stroke: standards and abnormal situations
Fonyakin, A. V., & Гераскина, Л. А. (2014) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2014-1-48-53 · Cited by 2
Transcatheter Closure of Atrial Septal Defects and Patent Foramen Ovale
Garay, F., Cao, Q., & Hijazi, Z. M. (2016) · Springer eBooks · doi:10.1007/978-1-4471-7290-1_32 · Cited by 2
New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention
Arnao, V., Riolo, M., Tuttolomondo, A., Pinto, A. V., Fierro, B., & Aridon, P. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1268053 · Cited by 2
“In WARSS [46], the long-term use of warfarin at an INR 1.4–2.8 was not superior to aspirin for the prevention of recurrent stroke among patients with non-cardioembolic stroke.”
BackgroundInfluentialAntiplatelet Therapy in Cerebrovascular Disorders
Spokoyny, I., & Albers, G. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_92 · Cited by 2
Self-citationGreer, D. M., Aparicio, H. J., Siddiqi, O. K., & Furie, K. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-69424-7.00032-6 · Cited by 2
Self-citationHira, K., Ueno, Y., Watanabe, M., Shimura, H., Kurita, N., Miyamoto, N., Haginiwa, H., Yamashiro, K., Hattori, N., & Urabe, T. (2022) · BMC Neurology · doi:10.1186/s12883-022-02867-z · Cited by 2
Chikumbanje, M. M., Raza, S. I., & Barham, L. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.04.005 · Cited by 2
Arterial Lesion Location and Outcomes of Intracranial Atherosclerotic Disease
Tariq, M. B., Kaneko, N., Prochilo, G., Hinman, J. D., & Liebeskind, D. S. (2024) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.124.001344 · Cited by 2
“10 Although previous studies have reported that the specific arterial location of stenosis is not associated with outcomes, in this review, we discuss how arterial segment lesion location is an understudied, yet important, variable in the treatment of ICAD.”
Therapeutic strategies and neurorehabilitation
Brainin, M., & Heiss, W. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107239340.018 · Cited by 2
Enfermedad cerebrovascular de pequeño vaso
Portela, P. C., & Avellaneda, A. E. (2018) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2018.04.002 · Cited by 4
Caplan, L. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4721-6.50007-9 · Cited by 2
Koschmieder, S. (2021) · Hemato · doi:10.3390/hemato2030025 · Cited by 2
“venous recurrence (history of remote thrombosis), both arterial and venous rethrombosis were prevented by VKA treatment [38], as has been shown for myocardial infarction [39] and ischemic stroke [40] in the non-MPN population.”
BackgroundForamen ovale permeable y ataque criptogénico: Papel de la ecocardiografía y estado del arte
Jaramillo, U., & Mario, H. (2008) · Revista Colombiana de Cardiología · Cited by 2
Pavlou, E., & Γκαμπέτα, Α. (2011) · DergiPark (Istanbul University) · doi:10.17334/jps.29293 · Cited by 2
Halkes, P. H. A., & Algra, A. (2007) · Cerebrovascular Diseases · doi:10.1159/000107385 · Cited by 2
“In this multicentre trial, patients with cerebral ischaemia of arterial origin were randomised between anticoagulants (aimed INR 3.0–4.5) and aspirin 30 mg daily. This trial was terminated at the first interim analysis because of safety reasons, after 1,316 patients had been randomised and a mean follow-up of 1.2 year…”
ResultInfluential29th International Stroke Conference, San Diego, California, February 5???7, 2004
Brown, D. L., & Mecozzi, A. C. (2004) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-200406000-00014 · Cited by 2
Advances in Imaging of Intracranial Atherosclerotic Disease and Implications for Treatment
Caprio, F. Z., & Prabhakaran, S. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0240-y · Cited by 2
Aortic Atheromas in Acute Ischemic Stroke Patients in Northern Israel
Telman, G., Kouperberg, E., Sprecher, E., & Agmon, Y. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.8334 · Cited by 2
Howard, V. J., Furie, K. L., Wang, C.-H., Sides, E. G., & Toole, J. F. (2006) · Neuroepidemiology · doi:10.1159/000096994 · Cited by 2
Self-citation
Metadata
- Authors
- Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., Jackson, C. M., & Pullicino, P.
- Affiliations
- Columbia University Irving Medical Center (US)
- Massachusetts General Hospital (US)
- Stanford Medicine (US)
- University of Kentucky (US)
- University of California San Diego (US)
- University at Buffalo, State University of New York (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11-15
- Volume
- 345
- Issue
- 20
- Pages
- 1444-1451
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2027538725
- Cited by
- 1,168
- References
- 39
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 13 · 2023: 22 · 2022: 20 · 2021: 40 · 2020: 24 · 2019: 37 · 2018: 32 · 2017: 33 · 2016: 50 · 2015: 41 · 2014: 54 · 2013: 39 · 2012: 49
- FWCI
- 54.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Yale University
- University of Southern California
- Vanderbilt University
- University of Miami
- Wayne State University
- Cleveland Clinic
- Cleveland Clinic Foundation
- Johns Hopkins University
- Hennepin County Medical Center
- University of South Alabama
- York University
- University of Illinois at Urbana-Champaign
- National Institute of Neurological Disorders and Stroke (R01NS028371)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, aspirin, recurrent ischemic stroke, secondary stroke prevention, antiplatelet therapy, major bleeding, non-cardioembolic stroke, lacunar infarction, cryptogenic stroke, international normalized ratio, anticoagulation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anticoagulants, Aspirin, Brain Ischemia, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Mortality, Platelet Aggregation Inhibitors, Risk Factors, Warfarin, International Normalized Ratio, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
